Pozen acquires Tribute Pharma (Canada) for $146 million.

Pozen Inc. announced the acquisition of Tribute Pharmaceuticals Canada Inc., a Canadian specialty pharmaceutical company, in a transaction valued at approximately $146 million. Upon completion of the acquisition, which is expected to occur in the fourth quarter of 2015, the combined company will be named Aralez Pharmaceuticals plc and be domiciled in Ireland. Upon closing, Aralez is expected to trade on NASDAQ and TSX. The acquisition will create a premier specialty pharmaceutical company with a broad portfolio of commercial products and a growth plan focused on innovative products and acquisitions and the commercialization of portfolio products in the United States and Canada. Today, Pozen's lead proprietary product is Yosprala, a coordinated-delivery tablet designed to provide the cardiovascular benefit of aspirin while reducing its gastrointestinal side effects. Pozen also has two commercial pain products, Vimovo and Treximet, which are marketed by partners worldwide. Tribute�s highly complementary portfolio includes Fibricor, Bezalip SR and Visken/Viskazide for various cardiovascular indications; Cambia and Fiorinal and Fiorinal C for acute migraines and tension headaches, respectively; and a range of other specialty products.